{"id":"NCT02087306","sponsor":"Chimerix","briefTitle":"Study to Assess the Safety and Efficacy of Brincidofovir in Treatment of Early Versus Late Adenovirus Infection","officialTitle":"A Phase 3, Open-Label, Multicenter Study of the Safety and Efficacy of Brincidofovir (CMX001) in the Treatment of Early Versus Late Adenovirus Infection","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2014-03","primaryCompletion":"2016-06","completion":"2016-08","firstPosted":"2014-03-14","resultsPosted":"2021-08-13","lastUpdate":"2021-08-13"},"enrollment":201,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Adenovirus Infection"],"interventions":[{"type":"DRUG","name":"Brincidofovir","otherNames":["BCV","CMX001"]}],"arms":[{"label":"Brincidofovir","type":"EXPERIMENTAL"}],"summary":"This was a Phase 3 open-label, non-randomized, multicenter study of oral brincidofovir (BCV) administered twice weekly for the treatment of adenovirus (AdV) infection detected during asymptomatic AdV viremia or during symptomatic AdV infection.","primaryOutcome":{"measure":"Number of Participants With All-Cause Mortality","timeFrame":"60 days","effectByArm":[{"arm":"Cohort A","deltaMin":9,"sd":null},{"arm":"Cohort B","deltaMin":27,"sd":null},{"arm":"Cohort C","deltaMin":8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"2 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":33,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":93,"n":130},"commonTop":["Diarrhoea","Acute graft versus host disease","Pyrexia","Vomiting","Abdominal pain"]}}